drugset
drugset / Trial / NCT04324905

Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP1802 to HGP1705 in Healthy Volunteers

NCT04324905 ↗

Phase 1 Completed 49 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

A Phase 1 Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP1802 to HGP1705 in Healthy Volunteers

Timeline

Start
2020-04-29
Primary completion
2020-10-30
Completion
2020-10-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 40 mg —
Subject magnesium hydroxide Unknown 350 mg —

Indications

No indication recorded.